top of page
.png)
Eyes on Pharma
Check-out What Intel Caught our Eye
Pharma Phriday (April 3, 2026)
Pharma Phriday (April 3, 2026): Clinical advances span sleep disorders, respiratory disease, dermatology, cardiovascular risk, and autoimmune conditions. Regulatory highlights cover diabetes, haematological malignancies, and biosimilars. Commercially, M&A activity dominated, alongside AI-driven R&D partnerships.
Duncan Emerton
Apr 330 min read
BioPharma M&A Update
According to an annual PwC study released in December, the amount of M&A activity in the pharmaceutical and life sciences sectors in 2024...
Jana Chisholm
Jan 20, 20256 min read
Eyes on 3Q24 Financial Results
We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.
Jana Chisholm
Dec 11, 202416 min read
bottom of page